On Apr. 29, 2020, Catalent announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalentﾒs Biologics business unit will accelerate availability of manufacturing capacity and prepare for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnsonﾒs lead vaccine candidate for COVID-19.